Abstract Number: 0437 • ACR Convergence 2024
Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…Abstract Number: 0577 • ACR Convergence 2024
AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
Background/Purpose: Data on fertility in women with spondyloarthritis (SpA) is sparse but seems to be impaired compared to the general population. Divergent results have been…Abstract Number: 1893 • ACR Convergence 2024
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…Abstract Number: 0035 • ACR Convergence 2024
Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA
Background/Purpose: It is well established that women develop RA approximately three times more often than men. In addition, several risk factors for RA uniquely effect…Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…Abstract Number: 0805 • ACR Convergence 2024
Results from the Certolizumab-pegol Pregnancy Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project
Background/Purpose: Certolizumab pegol (CZP) is a tumor necrosis factor (TNF) blocker first approved in the U.S. in 2008. CZP is approved for the treatment of…Abstract Number: 2165 • ACR Convergence 2024
Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease
Background/Purpose: Adolescents and young adults diagnosed with rheumatic diseases often require treatment with teratogenic and cytotoxic medications to effectively manage their conditions. While these therapies…Abstract Number: 0184 • ACR Convergence 2024
Improving Age Disparities in Contraceptive Counseling in Women with Lupus: A Quality Improvement Initiative
Background/Purpose: Lupus is an autoimmune disease primarily affecting women of reproductive age. Lupus confers an increased risk of adverse maternal fetal outcomes, and pre-pregnancy planning…Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…Abstract Number: 2398 • ACR Convergence 2024
The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus
Background/Purpose: To identify whether serum 25-Hydroxyvitamin D (25(OH)D) level in first-trimester(before13 weeks of gestation) maternal is associated with pregnancy outcomes in patients with systemic lupus…Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…Abstract Number: 0440 • ACR Convergence 2024
Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Background/Purpose: Women with systemic lupus erythematosus (SLE) have increased rates of pre-term birth, small for gestational age babies, and pre-eclampsia compared to women without a…Abstract Number: 0807 • ACR Convergence 2024
Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents substantial risks for both maternal cardiovascular events (CVEs) and adverse pregnancy outcomes, yet, the influence of maternal CVEs on…Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 19
- Next Page »